Optimized dithranol-imiquimod-based transcutaneous immunization enables tumor rejection

INTRODUCTION: Transcutaneous immunization (TCI) is a non-invasive vaccination method promoting strong cellular immune responses, crucial for the immunological rejection of cancer. Previously, we reported on the combined application of the TLR7 agonist imiquimod (IMQ) together with the anti-psoriatic...

Descripción completa

Detalles Bibliográficos
Autores principales: Hartmann, Ann-Kathrin, Bartneck, Joschka, Pielenhofer, Jonas, Meiser, Sophie Luise, Arnold-Schild, Danielle, Klein, Matthias, Stassen, Michael, Schild, Hansjörg, Muth, Sabine, Probst, Hans Christian, Langguth, Peter, Grabbe, Stephan, Radsak, Markus P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505723/
https://www.ncbi.nlm.nih.gov/pubmed/37727790
http://dx.doi.org/10.3389/fimmu.2023.1238861

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505723/
https://www.ncbi.nlm.nih.gov/pubmed/37727790
http://dx.doi.org/10.3389/fimmu.2023.1238861

Ejemplares similares